We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · May 25, 2022

Long-Term Efficacy, Safety, and Neurotolerability of the MATRix Regimen Followed by Autologous Transplant in Primary CNS Lymphoma



Additional Info

Disclosure statements are available on the authors' profiles:

Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial
Leukemia 2022 May 13;[EPub Ahead of Print], AJM Ferreri, K Cwynarski, E Pulczynski, CP Fox, E Schorb, C Celico, M Falautano, A Nonis, P La Rosée, M Binder, A Fabbri, F Ilariucci, M Krampera, A Roth, C Hemmaway, PW Johnson, KM Linton, T Pukrop, JS Gørløv, M Balzarotti, G Hess, U Keller, S Stilgenbauer, J Panse, A Tucci, L Orsucci, F Pisani, M Zanni, SW Krause, HJ Schmoll, B Hertenstein, M Rummel, J Smith, L Thurner, G Cabras, E Pennese, M Ponzoni, M Deckert, LS Politi, J Finke, A Ferranti, K Cozens, E Burger, N Ielmini, F Cavalli, E Zucca, G Illerhaus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Brain Cancer Center of Excellence

Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.

Further Reading